These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16331501)

  • 1. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
    Brantley E; Antony S; Kohlhagen G; Meng L; Agama K; Stinson SF; Sausville EA; Pommier Y
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):62-72. PubMed ID: 16331501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
    Trapani V; Patel V; Leong CO; Ciolino HP; Yeh GC; Hose C; Trepel JB; Stevens MF; Sausville EA; Loaiza-Pérez AI
    Br J Cancer; 2003 Feb; 88(4):599-605. PubMed ID: 12592376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
    Leong CO; Gaskell M; Martin EA; Heydon RT; Farmer PB; Bibby MC; Cooper PA; Double JA; Bradshaw TD; Stevens MF
    Br J Cancer; 2003 Feb; 88(3):470-7. PubMed ID: 12569393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
    Leong CO; Suggitt M; Swaine DJ; Bibby MC; Stevens MF; Bradshaw TD
    Mol Cancer Ther; 2004 Dec; 3(12):1565-75. PubMed ID: 15634650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
    Brantley E; Trapani V; Alley MC; Hose CD; Bradshaw TD; Stevens MF; Sausville EA; Stinson SF
    Drug Metab Dispos; 2004 Dec; 32(12):1392-401. PubMed ID: 15355884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.
    McLean LS; Watkins CN; Campbell P; Zylstra D; Rowland L; Amis LH; Scott L; Babb CE; Livingston WJ; Darwanto A; Davis WL; Senthil M; Sowers LC; Brantley E
    Chem Res Toxicol; 2015 May; 28(5):855-71. PubMed ID: 25781201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines.
    Bradshaw TD; Stone EL; Trapani V; Leong CO; Matthews CS; te Poele R; Stevens MF
    Breast Cancer Res Treat; 2008 Jul; 110(1):57-68. PubMed ID: 17674193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.
    Brantley E; Patel V; Stinson SF; Trapani V; Hose CD; Ciolino HP; Yeh GC; Gutkind JS; Sausville EA; Loaiza-Pérez AI
    Anticancer Drugs; 2005 Feb; 16(2):137-43. PubMed ID: 15655410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.
    Monks A; Harris E; Hose C; Connelly J; Sausville EA
    Mol Pharmacol; 2003 Mar; 63(3):766-72. PubMed ID: 12606787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
    Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
    Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
    Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
    Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antitumour activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole in human gastric cancer models is mediated by AhR signalling.
    Wang Y; Liu Y; Tang T; Luo Y; Stevens MFG; Cheng X; Yang Y; Shi D; Zhang J; Bradshaw TD
    J Cell Mol Med; 2020 Jan; 24(2):1750-1759. PubMed ID: 31876059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).
    Bradshaw TD; Chua MS; Orr S; Matthews CS; Stevens MF
    Br J Cancer; 2000 Jul; 83(2):270-7. PubMed ID: 10901382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
    Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
    Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
    Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
    Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
    Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
    Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
    Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
    Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.